AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 4056780 — intervention group
Group type: EXPERIMENTAL
Intervention: MOMMY AND I ARE ONE (subliminal exposure with pictures)
Number of subjects: 128
Study 4056780 — intervention group
Group type: EXPERIMENTAL
Intervention: MOMMY AND I ARE ONE (subliminal exposure without pictures)
Number of subjects: 128
Study 4056780 — intervention group
Group type: EXPERIMENTAL
Intervention: Other experimental stimuli (MOMMY IS ALWAYS WITH ME, MOMMY FEEDS ME WELL, I CANNOT HURT MOMMY)
Number of subjects: 128
Study 4056780 — intervention group
Group type: COMPARATOR
Intervention: Control stimulus (PEOPLE ARE WALKING)
Number of subjects: 128
Study 30354562 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH/SRD (Dietary Approaches to Stop Hypertension meals; 1500 mg sodium/d)
Number of subjects: 66
Study 30354562 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH/SRD
Number of subjects: 66
Study 30354562 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 66
Study 27535783 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate 150mg/month
Number of subjects: 62
Study 27535783 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 35mg/week
Number of subjects: 62
Study 27535783 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70mg/week
Number of subjects: 62
Study 27535783 — intervention group
Group type: COMPARATOR
Intervention: Control group (25 healthy premenopausal women, mean age 37)
Number of subjects: 62
Study 24958563 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine
Number of subjects: 9
Study 24958563 — intervention group
Group type: EXPERIMENTAL
Intervention: Dealcoholized red wine
Number of subjects: 9
Study 24958563 — intervention group
Group type: COMPARATOR
Intervention: Gin
Number of subjects: 9
Study 24958563 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacteria (highest tertile)
Number of subjects: 9
Study 24958563 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacteria changes
Number of subjects: 9
Study 24958563 — intervention group
Group type: EXPERIMENTAL
Intervention: Syringic acid and 4‐hydroxybenzoic acid changes
Number of subjects: 9
Study 22678051 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (237 ml, 182 mg caffeine)
Number of subjects: 106
Study 22678051 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee (237 ml, 4 mg caffeine)
Number of subjects: 106
Study 20546197 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified sequential three-step empirical therapy
Number of subjects: 240
Study 20546197 — intervention group
Group type: COMPARATOR
Intervention: Primary sequential three-step empirical therapy
Number of subjects: 240
Study 18509926 — intervention group
Group type: EXPERIMENTAL
Intervention: Complexes of physical and respiratory exercises according to developed medical technology
Number of subjects: 177
Study 15697327 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine 15-60 mg/day (n = 147)
Number of subjects: 297
Study 15697327 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 20-40 mg/day (n = 152)
Number of subjects: 297
Study 15697327 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 297
Study 11319711 — intervention group
Group type: EXPERIMENTAL
Intervention: Bergman minimal model (BMM) with 3-hour IVGTT
Number of subjects: 8
Study 11319711 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified model with delay (MMD) and 5-hour IVGTT
Number of subjects: 8
Study 11319711 — intervention group
Group type: COMPARATOR
Intervention: Type 2 diabetes patients (Si)
Number of subjects: 8
Study 11319711 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-stage euglycemic clamp (Si)
Number of subjects: 8
Study 11319711 — intervention group
Group type: COMPARATOR
Intervention: Type 2 diabetes patients (Sg)
Number of subjects: 8
Study 11319711 — intervention group
Group type: COMPARATOR
Intervention: Normal nondiabetic subjects using MMD
Number of subjects: 8
Study 10971979 — intervention group
Group type: EXPERIMENTAL
Intervention: Zuclopenthixol acetate
Number of subjects: 50
Study 10971979 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 50
Study 7805082 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 1000
Study 7805082 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1000
Study 7805082 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin and Aspirin combination
Number of subjects: 1000
Study 7805082 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Warfarin
Number of subjects: 1000
Study 2686257 — intervention group
Group type: EXPERIMENTAL
Intervention: ISDN/ISMN (120 mg/50 mg) + Diltiazem (D)
Number of subjects: 11
Study 2686257 — intervention group
Group type: EXPERIMENTAL
Intervention: ISDN/ISMN (120 mg/50 mg)
Number of subjects: 11
Study 2686257 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with Diltiazem (D)
Number of subjects: 11
Study 2686257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 4837255 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative irradiation + surgery ad modum Wertheim
Number of subjects: 50
Study 4837255 — intervention group
Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 50
Study 30786930 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured antenatal pelvic floor muscle exercise (PFME) programme combined with standard antenatal care
Number of subjects: 200
Study 30786930 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care alone
Number of subjects: 200
Study 30786930 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercise (PFME)
Number of subjects: 200
Study 28550895 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultracision
Number of subjects: 99
Study 28550895 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure
Number of subjects: 99
Study 28550895 — intervention group
Group type: EXPERIMENTAL
Intervention: MiSeal
Number of subjects: 99
Study 28550895 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 99
Study 27844472 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol PR (100-250 mg bid)
Number of subjects: 2968
Study 27844472 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone CR (20-50 mg bid)
Number of subjects: 2968
Study 27844472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2968
Study 24831754 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual drug counseling in addition to buprenorphine-naloxone and medical management
Number of subjects: 0
Study 24831754 — intervention group
Group type: COMPARATOR
Intervention: Medical management alone
Number of subjects: 0
Study 22540417 — intervention group
Group type: EXPERIMENTAL
Intervention: FertilMate™ Scrotum Cooling Patch for 90 days
Number of subjects: 40
Study 22540417 — intervention group
Group type: COMPARATOR
Intervention: Control group (not wearing patches)
Number of subjects: 40
Study 19398797 — intervention group
Group type: EXPERIMENTAL
Intervention: Kite method
Number of subjects: 42
Study 19398797 — intervention group
Group type: COMPARATOR
Intervention: Ponseti method
Number of subjects: 42
Study 17135328 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance knowledge of PSA testing (informed consent prior to reporting)
Number of subjects: 210
Study 17135328 — intervention group
Group type: COMPARATOR
Intervention: No advance knowledge of PSA testing (informed consent after reporting)
Number of subjects: 210
Study 17135328 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance knowledge of PSA testing
Number of subjects: 210
Study 17135328 — intervention group
Group type: COMPARATOR
Intervention: No advance knowledge of PSA testing
Number of subjects: 210
Study 15356066 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (1 microg/kg)
Number of subjects: 10
Study 15356066 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (1 microg/kg) in GHRP-2-stimulated setting
Number of subjects: 10
Study 15356066 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (1 microg/kg) in GHRH and combined GHRH/GHRP-2-stimulated contexts
Number of subjects: 10
Study 11421509 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol added to budesonide
Number of subjects: 0
Study 11421509 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol added to low dose budesonide
Number of subjects: 0
Study 11421509 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol added to moderate doses of budesonide
Number of subjects: 0
Study 9678398 — intervention group
Group type: EXPERIMENTAL
Intervention: Community intervention (community organization and public, patient, and health professional education)
Number of subjects: 0
Study 9678398 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison)
Number of subjects: 0
Study 7733470 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 to 0.75 mg/kg)
Number of subjects: 116
Study 7733470 — intervention group
Group type: EXPERIMENTAL
Intervention: Trilene (0.3 to 0.5 vol.%)
Number of subjects: 116
Study 7733470 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramal
Number of subjects: 116
Study 7733470 — intervention group
Group type: EXPERIMENTAL
Intervention: Nubain
Number of subjects: 116
Study 7733470 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondrug warming measures
Number of subjects: 116
Study 2644050 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 0.2 mg.kg‐1 (Group V)
Number of subjects: 0
Study 2644050 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 0.15 mg.kg‐1 (Group IV)
Number of subjects: 0
Study 2644050 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 0.1 mg.kg‐1 (Group III)
Number of subjects: 0
Study 2644050 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 0.05 mg.kg‐1 (Group II)
Number of subjects: 0
Study 2644050 — intervention group
Group type: COMPARATOR
Intervention: Edrophonium 1.0 mg.kg‐1 (Group I, controls)
Number of subjects: 0
Study 4911774 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 therapy
Number of subjects: 39
Study 4911774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 31709970 — intervention group
Group type: EXPERIMENTAL
Intervention: Pearl millet porridge (PMP)
Number of subjects: 26
Study 31709970 — intervention group
Group type: COMPARATOR
Intervention: Scottish oats porridge (SOP)
Number of subjects: 26
Study 27898491 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine
Number of subjects: 89
Study 27898491 — intervention group
Group type: COMPARATOR
Intervention: Intravenous naloxone
Number of subjects: 89
Study 27898491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 25659256 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous PRP (platelet-rich plasma) used in skin transplantation
Number of subjects: 4
Study 25659256 — intervention group
Group type: COMPARATOR
Intervention: Standard skin transplantation without PRP
Number of subjects: 4
Study 23659557 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ‐5D‐3L
Number of subjects: 0
Study 23659557 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ‐5D VAS
Number of subjects: 0
Study 23659557 — intervention group
Group type: EXPERIMENTAL
Intervention: SF‐6D
Number of subjects: 0
Study 23659557 — intervention group
Group type: EXPERIMENTAL
Intervention: SF‐12 new algorithm
Number of subjects: 0
Study 23659557 — intervention group
Group type: EXPERIMENTAL
Intervention: All instruments
Number of subjects: 0
Study 23659557 — intervention group
Group type: EXPERIMENTAL
Intervention: SF‐6D and SF‐12
Number of subjects: 0
Study 22050864 — intervention group
Group type: EXPERIMENTAL
Intervention: Blastocyst-stage embryo transfer
Number of subjects: 200
Study 22050864 — intervention group
Group type: COMPARATOR
Intervention: Cleavage-stage embryo transfer
Number of subjects: 200
Study 19276838 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week multidisciplinary physical activity behavior change intervention
Number of subjects: 41
Study 19276838 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 41
Study 17901611 — intervention group
Group type: EXPERIMENTAL
Intervention: P'ASMA (web-based asthma self-management support tool)
Number of subjects: 21
Study 17901611 — intervention group
Group type: COMPARATOR
Intervention: Paper-based asthma diary and action-plan
Number of subjects: 21
Study 15279527 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-delivered personalized normative feedback intervention
Number of subjects: 252
Study 15279527 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 252
Study 11485076 — intervention group
Group type: EXPERIMENTAL
Intervention: Phyllanthus amarus compound (PA Co)
Number of subjects: 55
Study 11485076 — intervention group
Group type: COMPARATOR
Intervention: Interferon alpha‐1b (IFN‐alpha 1b)
Number of subjects: 55
Study 9202362 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 0
Study 2292635 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertion Training (AT)
Number of subjects: 46
Study 2292635 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly Assertion Training Boosters (ATB)
Number of subjects: 46
Study 2292635 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly Attention Placebo Boosters (APB)
Number of subjects: 46
Study 2292635 — intervention group
Group type: COMPARATOR
Intervention: No Boosters (NB)
Number of subjects: 46
Study 6108780 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (ME) 75 mg to 242 mg
Number of subjects: 9
Study 6108780 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (PI) 7.5 mg to 23 mg
Number of subjects: 9
Study 6108780 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (PR) 60 mg to 233 mg
Number of subjects: 9
Study 6108780 — intervention group
Group type: COMPARATOR
Intervention: Control (Isoprenaline)
Number of subjects: 9
Study 6108780 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (ME)
Number of subjects: 9
Study 6108780 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (PI)
Number of subjects: 9
Study 6108780 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (PR)
Number of subjects: 9
Study 31655603 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-HG (2.2 g CHO-HG·min-1)
Number of subjects: 12
Study 31655603 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-HG
Number of subjects: 12
Study 31655603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 28343975 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine 2.4 mg/kg weekly
Number of subjects: 415
Study 28343975 — intervention group
Group type: COMPARATOR
Intervention: Taxane
Number of subjects: 415
Study 26430724 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus fludarabine plus cyclophosphamide
Number of subjects: 329
Study 26430724 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine plus cyclophosphamide alone
Number of subjects: 329
Study 24657236 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab 450 mg
Number of subjects: 32
Study 24657236 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab 525 mg
Number of subjects: 32
Study 24657236 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab 600 mg
Number of subjects: 32
Study 24657236 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (all doses)
Number of subjects: 32
Study 22537466 — intervention group
Group type: EXPERIMENTAL
Intervention: Ping Shuai Qigong intervention group
Number of subjects: 70
Study 22537466 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 20668329 — intervention group
Group type: EXPERIMENTAL
Intervention: In house autologous platelet gel
Number of subjects: 100
Study 20668329 — intervention group
Group type: COMPARATOR
Intervention: Vivostat‐ gel
Number of subjects: 100
Study 18970976 — intervention group
Group type: EXPERIMENTAL
Intervention: BG00012 240 mg three times daily
Number of subjects: 257
Study 18970976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study 16102623 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel and aspirin
Number of subjects: 132
Study 16102623 — intervention group
Group type: COMPARATOR
Intervention: Placebo and aspirin
Number of subjects: 132
Study 11796288 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspicious DRE findings indicating extracapsular disease
Number of subjects: 2199
Study 11796288 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspicious TRUS findings indicating extracapsular disease
Number of subjects: 2199
Study 9989124 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50-100 mg per day for 8 weeks
Number of subjects: 768
Study 9989124 — intervention group
Group type: COMPARATOR
Intervention: Control group (psychiatric office practice)
Number of subjects: 768
Study 9989124 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (primary care and psychiatric office practice)
Number of subjects: 768
Study 8626939 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA
Number of subjects: 5711
Study 8626939 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 5711
Study 1462277 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenormin (atenolol) 100 mg daily
Number of subjects: 20
Study 1462277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3882061 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg three times a day for two weeks
Number of subjects: 16
Study 3882061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31294599 — intervention group
Group type: EXPERIMENTAL
Intervention: parent wise feedback intervention
Number of subjects: 51
Study 27487786 — intervention group
Group type: EXPERIMENTAL
Intervention: Chang'an I Recipe
Number of subjects: 216
Study 27487786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 26561390 — intervention group
Group type: EXPERIMENTAL
Intervention: A/H5N1 vaccine with AS03 adjuvant
Number of subjects: 0
Study 25060370 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg
Number of subjects: 333
Study 25060370 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 150 mg
Number of subjects: 333
Study 25060370 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (both doses)
Number of subjects: 333
Study 23249323 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytrip tickets for the whole family to a popular amusement park if they returned all postal questionnaires
Number of subjects: 771
Study 23249323 — intervention group
Group type: EXPERIMENTAL
Intervention: €12.50-worth gift vouchers for sending back the questionnaire on time after each questionnaire round
Number of subjects: 771
Study 23249323 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of daytrip tickets and gift vouchers
Number of subjects: 771
Study 23249323 — intervention group
Group type: COMPARATOR
Intervention: Control group (no incentives)
Number of subjects: 771
Study 20353117 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuina treatment
Number of subjects: 0
Study 20353117 — intervention group
Group type: COMPARATOR
Intervention: Control group (rest)
Number of subjects: 0
Study 17545357 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable ankle brace
Number of subjects: 104
Study 17545357 — intervention group
Group type: COMPARATOR
Intervention: Below-knee walking cast
Number of subjects: 104
Study 15723869 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard periodontal therapy (SPT)
Number of subjects: 65
Study 15723869 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive periodontal therapy (IPT)
Number of subjects: 65
Study 15723869 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 65
Study 12049860 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg fondaparinux once daily
Number of subjects: 2275
Study 12049860 — intervention group
Group type: COMPARATOR
Intervention: 30 mg enoxaparin twice daily
Number of subjects: 2275
Study 12049860 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 2275
Study 9866433 — intervention group
Group type: EXPERIMENTAL
Intervention: Distant Healing (DH) treatment for 10 weeks
Number of subjects: 40
Study 7839424 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-match study (CS) patients with detectable lymphocytotoxic antibodies (LA)
Number of subjects: 510
Study 7839424 — intervention group
Group type: COMPARATOR
Intervention: Antigen matching study (AMS) patients without detectable LA
Number of subjects: 510
Study 7839424 — intervention group
Group type: COMPARATOR
Intervention: Comparison of graft survival between CS and AMS patients
Number of subjects: 510
Study 2126584 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aspirin (100 mg/kg/day)
Number of subjects: 60
Study 2126584 — intervention group
Group type: COMPARATOR
Intervention: Low-dose aspirin (30 mg/kg/day)
Number of subjects: 60
Study 94871 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Number of subjects: 1340
Study 94871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1340
Study 30924129 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphs with contextual information
Number of subjects: 0
Study 30924129 — intervention group
Group type: COMPARATOR
Intervention: Graphs without contextual information
Number of subjects: 0
Study 31052297 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolyzed porcine proteins from blood (HPB)
Number of subjects: 18
Study 31052297 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolyzed porcine proteins from muscle (HPM)
Number of subjects: 18
Study 31052297 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolyzed whey protein (HW)
Number of subjects: 18
Study 31052297 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolyzed porcine proteins from blood (HPB) and hydrolyzed whey protein (HW)
Number of subjects: 18
Study 28206788 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectations for antibiotics (Experiment 1)
Number of subjects: 436
Study 28206788 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectations for antibiotics (Experiment 2)
Number of subjects: 436
Study 26323830 — intervention group
Group type: EXPERIMENTAL
Intervention: Value-based cognitive-behavioural therapy (V-CBT) delivered within the first three months after a whiplash injury.
Number of subjects: 0
Study 26323830 — intervention group
Group type: COMPARATOR
Intervention: Delayed onset of V-CBT (3 months after randomization).
Number of subjects: 0